Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism

American Journal of Physiology - Endocrinology and Metabolism

Volumn 292, Issue 5, 2007, Pages

  Reppe, Sjur ^a   Stilgren, Lis ^b   Abrahamsen, Bo ^b   Olstad, Ole K ^c   Cero, Fadila ^c   Brixen, Kim ^b   Nissen Meyer, Lise Sofie ^a   Gautvik, Kaare M ^a,c,d,e  

^a UNIVERSITY OF OSLO   (Norway)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^e NONE   (Norway)

Author keywords

Biopsies; Microarray; Parathyroid hormone

Indexed keywords

MESSENGER RNA; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BIOPSY; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GENE EXPRESSION; HEMATOPOIESIS; HUMAN; MICROARRAY ANALYSIS; MORBIDITY; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; BIOPSY; GENE EXPRESSION REGULATION; HEMATOPOIETIC SYSTEM; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MIDDLE AGED; MUSCLES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARATHYROID HORMONE; RECEPTOR, PARATHYROID HORMONE, TYPE 1; RECEPTOR, PARATHYROID HORMONE, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34247619806     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00487.2006     Document Type: Article

References (50)

1. Albes B, Bazex J, Bayle-Lebey P, Bennet A, Lamant L. Primary hyperparathyroidism and cutaneous T-cell lymphoma: fortuitous association? Dermatology 203: 162-164, 2001.
2. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease-a review. Eur Heart J 25: 1776-1787, 2004.
3. Backlund LM, Grander D, Brandt L, Hall P, Ekbom A. Parathyroid adenoma and primary CNS tumors. Int J Cancer 113: 866-869, 2005.
4. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature 425: 841-846, 2003.
5. Charge SB, Rudnicki MA. Cellular and molecular regulation of muscle regeneration. Physiol Rev 84: 209-238, 2004.
6. Cholod EJ, Haust MD, Hudson AJ, Lewis FN. Myopathy in primary familial hyperparathyroidism. Clinical and morphologic studies. Am J Med 48: 700-707, 1970.
7. Clark OH. Diagnosis of primary hyperparathyroidism. In: Textbook of Endocrine Surgery, edited by Clark OH and Duh G-Y. Philadelphia, PA: Saunders, 1997, p. 297-301.
8. Costa EM, Blau HM, Feldman D. 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 119: 2214-2220, 1986.
9. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 109: 67-79, 2002.
10. Divieti P, Inomata N, Chapin K, Singh R, Juppner H, Bringhurst FR. Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142: 916-925, 2001.
11. Dokmetas HS, Turkay C, Aydin C, Arici S. Prevalence of Helicobacter pylori in patients with primary hyperparathyroidism. J Bone Miner Metab 19: 373-377, 2001.
12. Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Yoshizawa T, Kato S, Matsumoto T. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 144: 5138-5144, 2003.
13. Feldman EC, Hoar B, Pollard R, Nelson RW. Pretreatment clinical and laboratory findings in dogs with primary hyperparathyroidism: 210 cases (1987-2004). J Am Vet Med Assoc 227: 756-761, 2005.
14. Gatewood JW, Organ CH Jr, Mead BT. Mental changes associated with hyperparathyroidism. Am J Psychiatry 132: 129-132, 1975.
15. Grey A, Mitnick MA, Shapses S, Ellison A, Gundberg C, Insogna K. Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption a clinical research center study. J Clin Endocrinol Metab 81: 3450-3454, 1996.
16. Guo CY, Holland PA, Jackson BF, Hannon RA, Rogers A, Harrison BJ, Eastell R. Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism. Eur J Endocrinol 142: 451-459, 2000.
17. Halabe A, Shohat B. Effect of parathyroid adenoma excision on interleukin-6 (IL-6) and IL-2 receptor levels. Metabolism 49: 192-194, 2000.
18. Harris SE, Yang W, Harris MA, Gluhak-Heinrich J, Bonewald LF, Rowe DW, Kalajzic I. Osteocyte gene expression signatures indicate that neural muscle and cytoskeletal genes as well as Wnt signaling represent novel pathways for osteocyte function (Abstract). J Bone Miner Res 21, Suppl 1: 1006, 2006.
19. Heath H 3rd, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302: 189-193, 1980.
20. Hedback G, Tisell LE, Bengtsson BA, Hedman I, Oden A. Premature death in patients operated on for primary hyperparathyroidism. World J Surg 14: 829-835, 1990.
21. Imai Y, Takahashi R. How do Parkin mutations result in neurodegeneration? Curr Opin Neurobiol 14: 384-389, 2004.
22. Inomata N, Akiyama M, Kubota N, Juppner H. Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 136: 4732-4740, 1995.
23. Joborn C, Hetta J, Johansson H, Rastad J, Agren H, Akerstrom G, Ljunghall S. Psychiatric morbidity in primary hyperparathyroidism. World J Surg 12: 476-481, 1988.
24. Joborn C, Hetta J, Lind L, Rastad J, Akerstrom G, Ljunghall S. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia. Surgery 105: 72-78, 1989.
25. Keys JR, Koch WJ. The adrenergic pathway and heart failure. Recent Prog Horm Res 59: 13-30, 2004.
26. Krebs LJ, Arnold A. Molecular basis of hyperparathyroidism and potential targets for drug development. Curr Drug Targets Immune Endocr Metabol Disord 2: 167-179, 2002.
27. Kuznetsov SA, Riminucci M, Ziran N, Tsutsui TW, Corsi A, Calvi L, Kronenberg HM, Schipani E, Robey PG, Bianco P. The interplay of osteogenesis and hematopoiesis: expression of a constitutively active PTH/PTHrP receptor in osteogenic cells perturbs the establishment of hematopoiesis in bone and of skeletal stem cells in the bone marrow. J Cell Biol 167: 1113-1122, 2004.
28. Lin R, White JH. The pleiotropic actions of vitamin D. BioEssays 26: 21-28, 2003.
29. Loh KC, Duh QY, Shoback D, Gee L, Siperstein A, Clark OH. Clinical profile of primary hyperparathyroidism in adolescents and young adults. Clin Endocrinol 48: 435-443, 1998.
30. Lotinun S, Sibonga JD, Turner RT. Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology 146: 4074-4081, 2005.
31. Lund PK, Joo GB, Westvik AB, Øvstebø R, Kierulf P. Isolation of monocytes from whole blood by density gradient centrifugation and counter-current elutriation followed by cryopreservation: six years' experience. Scand J Clin Lab Invest 60: 357-365, 2000.
32. Michels KB, Xue F, Brandt L, Ekbom A. Hyperparathyroidism and subsequent incidence of breast cancer. Int J Cancer 110: 449-451, 2004.
33. Mole PA, Walkinshaw MH, Gunn A, Paterson CR. Bone mineral content in patients with primary hyperparathyroidism: a comparison of conservative management with surgical treatment. Br J Surg 79: 263-265, 1992.
34. Nakchbandi IA, Mitnick MA, Lang R, Gundberg C, Kinder B, Insogna K. Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 87: 4946-4951, 2002.
35. Reppe S, Stilgren L, Olstad OK, Brixen K, Nissen-Meyer LS, Gautvik KM, Abrahamsen B. Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. Bone 39: 189-198, 2006.
36. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24: 2054-2060, 2003.
37. Saucerman JJ, Brunton LL, Michailova AP, McCulloch AD. Modeling β-adrenergic control of cardiac myocyte contractility in silico. J Biol Chem 278: 47997-48003, 2003.
38. Schipani E, Karga H, Karaplis AC, Potts JT Jr, Kronenberg HM, Segre GV, Abou-Samra AB, Juppner H. Identical complementary deoxyribonucleic acids encode a human renal and bone parathyroid hormone (PTH)/PTH-related peptide receptor. Endocrinology 132: 2157-2165, 1993.
39. Seeliger S, Hausberg M, Eue I, Usdin T, Rahn KH, Kosch M. The parathyroid hormone-2 receptor is expressed on human leukocytes and down-regulated in hyperparathyroidism. Clin Nephrol 59: 429-435, 2003.
40. Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exper Cell Res 175: 266-276, 1988.
41. Silverberg SJ, Shane E, De La Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL, Bilezekian JP. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4: 283-291, 1989.
42. Solomon BL, Schaaf M, Smallridge RC. Psychologic symptoms before and after parathyroid surgery. Am J Med 96: 101-106, 1994.
43. Spivak B, Radvan M, Ohring R, Weizman A. Primary hyperparathyroidism, psychiatric manifestations, diagnosis and management. Psychother Psychosom 51: 38-44, 1989.
44. Steinman RA. Cell cycle regulators and hematopoiesis. Oncogene 21: 3403-3413, 2002.
45. Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E, Cheng T, Dombkowski D, Calvi LM, Rittling SR, Scadden DT. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 201: 1781-1791, 2005.
46. Urena P, Kong XF, Abou-Samra AB, Juppner H, Kronenberg HM, Potts JT Jr, Segre GV. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 133: 617-623, 1993.
47. Usdin TB, Gruber C, Bonner TI. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem 270: 15455-15458, 1995.
48. Utiger RD. Treatment of primary hyperparathyroidism. N Engl J Med 341: 1301-1302, 1999.
49. Wishart J, Horowitz M, Need A, Chatterton B, Nordin BE. Treatment of postmenopausal hyperparathyroidism with norethindrone. Long-term effects on forearm mineral content. Arch Intern Med 150: 1951-1953, 1990.
50. Zatz M, Starling A. Calpains and disease. N Engl J Med 352: 2413-2423, 2005.